---
title: "GENinCode Shares Jump 23% as CARDIO inCode Study Shows Improved Coronary Risk Prediction"
publisher: "Share Talk"
author: "sharetalk"
published: "2026-08-28T08:44:34+00:00"
modified: "2026-08-28T08:53:22+00:00"
date: 2026-08-28
canonical: "https://www.share-talk.com/genincode-shares-jump-23-as-cardio-incode-study-shows-improved-coronary-risk-prediction/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["cholesterol", "GENI", "GENinCode PLC"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/GP99eq7WwAA9ZZB.jpg?fit=1200%2C825&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# GENinCode Shares Jump 23% as CARDIO inCode Study Shows Improved Coronary Risk Prediction

**Published:** August 28, 2026
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** cholesterol, GENI, GENinCode PLC
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/GP99eq7WwAA9ZZB.jpg?fit=1200%2C825&quality=89&ssl=1)

---

[GENinCode Plc (AIM: GENI)](https://www.investegate.co.uk/announcement/rns/genincode--geni/cardio-incode-score-milestone-clinical-results-/9744363)shares rose around **23% in early trading** after the predictive genetics company reported encouraging clinical results for its CARDIO inCode-Score® test in the prevention of coronary artery disease.

The Institut Català de la Salut, part of the Government of Catalonia, presented the preliminary results at the **European Society of Cardiology Annual Congress 2026 in Munich**.

The real-world pilot involved **584 patients across 14 primary care centres in Catalonia**, all aged between 45 and 65 and previously classified as having moderate cardiovascular risk using conventional clinical assessment.

When CARDIO inCode-Score® genetic risk data was added to conventional risk factors, the overall cardiovascular risk assessment changed in **42.6% of patients**. Around **26.5% moved into a different risk category outright**, with some patients reclassified upward and others downward.

The study also recorded improvements in modifiable cardiovascular risk factors following disclosure of the genetic results. Average estimated cardiovascular risk fell from **7.30% to 6.04%**, while mean LDL cholesterol declined from **136.74 mg/dL to 123.17 mg/dL** after an average follow-up of 8.5 months.

Smoking abstinence among the study cohort also increased from **43.7% to 62.8%**, with the reported changes achieving statistical significance.

The greatest benefit was seen among patients with the highest genetic risk, with **49.6% of that group moving to a lower risk category**, compared with 33% in the moderate genetic-risk group and 28.6% among those in the lowest quintile.

GENinCode said the findings provide further real-world evidence that polygenic risk scores can improve cardiovascular risk stratification and potentially allow clinicians to intensify prevention in higher-risk patients while reducing unnecessary intervention in those with lower inherited risk.

Further effectiveness and cost-effectiveness analysis is continuing.

---

**Original URL:** https://www.share-talk.com/genincode-shares-jump-23-as-cardio-incode-study-shows-improved-coronary-risk-prediction/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*